Humanigen Inc (fka HGENQ)

[cowtown jay]

Don't underestimate leronlimab, friend. The FDA's decision two days ago to allow the resumption of the use of leronlimab for EIND patients was followed up today with FDA guidance for CYDY on adding an open label extension for doctors wanting to use leronlimab in the Phase III trial.

I want HGEN management to be fully aware of the need to pull the trigger if the gun is loaded. If they have told themselves that it would be better to finish enrollment and not to take advantage of the 75% interim review data, I'm not sure they appreciated how close CYDY is to crossing the finish line, assuming they don't get Mesoblasted (rejected for failing to meet primary endpoint in reducing mortality).